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Abstract
Background—Among patients with heart failure (HF), anxiety symptoms may co-exist with
depressive symptoms. However, the extent of overlap and risk factors for anxiety symptoms have
not been thoroughly described.
Purpose—To describe the coexistence of anxiety and depressive symptoms, and to determine the
predictors of anxiety symptoms in patients with HF.
Methods—The sample consisted of 556 outpatients with HF (34% female, 62±12 years, 54%
NYHA class III/IV) enrolled in a multicenter HF quality of life registry. Anxiety symptoms were
assessed with the Brief Symptom Inventory-anxiety subscale. Depressive symptoms were
measured with the Beck Depression Inventory-II (BDI). We used a cut-point of 0.35 to categorize
patients as having anxiety symptoms or no anxiety symptoms. Logistic regression was used to
determine whether age, gender, minority status, educational level, functional status, comorbidities,
depressive symptoms, and antidepressant use were predictors of anxiety symptoms.
Results—One-third of patients had both depressive and anxiety symptoms. There was a dose-
response relationship between depressive symptoms and anxiety symptoms; higher levels of
depressive symptoms were associated with a higher level of anxiety symptoms. Younger age
(OR= 0.97, p = .004, 95% CI 0.95–0.99) and depressive symptoms (OR = 1.25, p < .001, 95% CI
1.19–1.31) were independent predictors of anxiety symptoms.
Conclusions—Patients with HF and depressive symptoms are at high risk for experiencing
anxiety symptoms. Clinicians should assess these patients for comorbid anxiety symptoms.
Research is needed to test interventions for both depressive and anxiety symptoms.
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Patients with HF frequently report symptoms of anxiety.1 Anxiety is a negative emotion that
occurs in response to perceived threats. Sources of anxiety can be internal or from outside
sources, and perceived threats can be real or imagined.2 On average, patients with HF have
much higher anxiety levels than healthy older adults.1 Surprisingly few researchers have
examined the relationship between anxiety and health outcomes in patients with HF.
However, several researchers have reported that the presence of anxiety symptoms is an
independent predictor of worsening functional status,3 poorer health-related quality of life,4
and more frequent re-hospitalizations.
In addition to experiencing anxiety symptoms, one-third of all patients with heart failure
(HF) experience depressive symptoms,6 which increase the risk for both poor health-related
quality of life4, 7 and shorter event-free survival.6 Depressive symptoms can be defined as
symptoms of anhedonia or low mood, accompanied by negative physical symptoms related
to activity, appetite, and sleep and/or negative cognitive symptoms related to ability to
concentrate, low self-worth, and pessimism about the future. Depressive symptoms may
exist with or without the presence of clinical depression,8 but they may differ from clinical
depression in the number, combination, and duration of symptoms, and in the degree to
which symptoms interfere with daily functioning.
It is possible that many patients with HF have co-existing symptoms of anxiety and
depression, as both are known to coexist in individuals with and without chronic disease.9
However, there has been little systematic quantitative research about the coexistence of
these two symptom domains in patients with HF. In a recent systematic review of qualitative
research,10 patients with HF and depressive symptoms disclosed that they were anxious
about many things, including: the future, comorbidities, the unpredictable nature of HF,
pain, hospital readmissions, medical procedures, the likelihood of a shortened life span, and
the possibility of dying in the middle of the night. One patient with HF described his fears
about an uncertain future: 8
“I just feel, you know, next week I might not be here…that’s my initial sort of fear,
you know, oh my God, how much longer have I got? (p. 276)”
Although many patients with HF experience symptoms of anxiety, others do not. Little is
known about characteristics of patients with and without anxiety symptoms, and which
independent risk factors may predispose patients with HF to anxiety. Furthermore, although
it is likely that anxiety and depressive symptoms are intertwined in patients with HF, we
have very little information about the coexistence of these two symptom domains.
Therefore, the specific aims of this study were to: 1) describe the characteristics of patients
with and without anxiety symptoms, 2) determine the extent to which anxiety and depressive
symptoms coexist in patients with HF, 3) determine whether depressive symptoms are an
independent predictor of the presence of anxiety symptoms
Methods
Design and Sample
This investigation was a cross-sectional, secondary data analysis of data from the Heart
Failure Quality of Life registry for patients with HF. A detailed summary of registry
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methods has been previously published.11, 12 The present subset (N = 556) is made up of a
convenience sample of subjects who had data on both depressive symptoms and anxiety
symptoms. Of registry sites, three collected the desired variables. Outpatients were recruited
from academic medical centers and community-based clinics in three Southeastern and
Midwestern states in the U.S.
Each of the registry studies conducted at these sites had similar inclusion and exclusion
criteria. Patients were eligible for inclusion if they had a diagnosis of chronic HF, preserved
or non-preserved systolic function, optimization on HF medications, taking stable
medication doses for 3 months, and English-speaking. Patients were excluded for a
myocardial infarction or unstable angina within 3 months, cognitive impairment that
precluded the ability to provide informed consent, placement at a skilled nursing facility, or
severe psychiatric impairment other than depression or anxiety.
Measurement
Anxiety symptoms—Anxiety was measured with the Brief Symptom Inventory (BSI)
anxiety subscale.13 This is a 6 item questionnaire that assesses the presence and intensity of
anxiety symptoms. Patients are asked to endorse how much they were distressed (0 = none
at all, 3 = extremely) by nervousness or shakiness inside, suddenly scared for no reason,
feeling fearful, feeling tense or keyed up, spells of terror or panic, and feeling so restless you
can’t sit still. Item scores are summed and averaged. According to published norms, the
mean anxiety level of healthy adults is 0.35, and the mean level of psychiatric inpatients and
outpatients is 1.7. Researchers have shown that the BSI anxiety subscale has good evidence
for reliability and validity in patients who are acutely ill. The BSI has demonstrated
excellent psychometric properties in patients with HF,14 and it performs better than the more
commonly used Spielberger State-Trait Index.15
Depressive symptoms—Depressive symptoms were measured with the Beck
Depression Inventory-II (BDI). This is a 21 item questionnaire in which patients report the
presence and severity of symptoms of depression. Patients who score a 14 or greater are
classified as having clinically significant depressive symptoms. Patients can also be
categorized as having none to minimal symptoms (0–13), mild symptoms (14–19), moderate
symptoms (20–28) or severe symptoms (29–63). Researchers have found good evidence for
reliability and validity of the BDI-II in both medical and non-medical populations.16, 17
Functional status—In patients with HF, worse functional status is closely related to
higher levels of anxiety3 and depressive symptoms.6 We measured functional status with the
New York Heart Association (NYHA) functional class and the Duke Activity Status Index
(DASI). NYHA class is a provider-rated indicator of functional status, based on the patient’s
subjective self-report of symptoms. On the basis of a clinical interview, patients are
classified from I to IV, with I indicating no symptoms, and IV indicating HF symptoms
occur even at rest.18 The DASI is a 12-item survey that measures functional capacity for
various activities of daily living.19 Total scores are calculated using a weighted score for
each activity; lower total scores indicate worse functional status.
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Other variables of interest—We used patient interviews to collect information on age,
sex, race/ethnicity, marital status, and education level. Chart reviews were used to collect
information on smoking status, ejection fraction, and medications. Medications were
confirmed by visually checking pill bottle prescriptions. Height and weight were measured
during the baseline visit. Data on comorbidities, were collected by patient interview using
the Charlson Comorbidity Index.20, 21
Protocol
Each of the individual studies was approved by local institutional review boards. The review
board at the primary author’s institution approved all secondary data analyses with the HF
registry as an exempt protocol. The investigation conformed to the principles outlined in the
Declaration of Helsinki. Patients were recruited in the outpatient setting and completed
written informed consent and baseline assessments at General Clinical Research Centers.
After completion of each study, data were de-identified and combined into a single HF
registry database at the primary author’s institution.
Data analysis
Data analysis was conducted using SPSS v. 20 (SPSS Inc, Chicago). A p value of less than .
05 was considered significant. Patient characteristics were described using means and
standard deviations or frequency distributions. A cut-point of 0.35 on the BSI-anxiety
subscale was used to divide patients into anxiety symptoms or no anxiety symptoms, and the
cut-point of 14 on the BDI-II was used to divide patients into depressive symptoms or no
depressive symptoms. Patients were also categorized as having: 1) both anxiety symptoms
and depressive symptoms, 2) anxiety symptoms alone, 3) depressive symptoms alone, and 4)
symptom-free. Differences in demographic and clinical variables between groups were
compared with independent t-tests, analysis of variance, and chi-square tests of association.
To further examine the relationship between severity of anxiety symptoms and severity of
depressive symptoms, we divided the sample into several sub-groups and used chi-square
tests of association to determine differences between these groups. To do so, we used the
cut-points of 0.35 and 1.7 on the BSI to form 3 groups: 1) below the mean anxiety level of
healthy adults (0 to 0.35), 2) in between the mean anxiety level of healthy adults and the
mean level of psychiatric outpatients (0.36 to 1.7), and 3) above the mean anxiety level of
psychiatric outpatients (>1.7). We also used BDI-II cut-points to label patients as having
none to minimal (0–13), mild (14–19), moderate (20–28), and severe (29–63) depressive
symptoms.
Finally, hierarchical logistic regression was used to determine the independent predictors of
anxiety symptom status. The independent variables entered consisted of block 1)
Demographics: age, gender, minority status, education level; block 2) HF severity and
comorbidities: NYHA class, DASI score, total comorbidity score: and block 3)
Psychological variables: depressive symptoms and antidepressant use. These variables were
chosen based on finding significant differences during bivariate analyses that compared
patients with and without anxiety symptoms (Table 2).
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Sample characteristics are described in Table 1. The final sample consisted of 556
outpatients with HF. One-third of the sample was female, and 36% were minorities.
Approximately half of the sample (54%) was classified as NYHA functional status class III
or IV, while 46% had NYHA Class I or II HF. Most of the patients were married (60%) and
lived with someone (70%), and 74% had at least a high school education (12 years of
school).
Depressive and anxiety symptoms
The mean BDI-II score for the entire sample was 12.3 ± 9.7, and 35% of the sample (n =
197) had clinically significant depressive symptoms. Fifty-four of the patients with
depressive symptoms were taking antidepressants (27.4%). Patients with depressive
symptoms had fewer years of education (10.8 vs. 13.5, p < .001), worse DASI scores (18.1
vs. 5.7, p < .001) and higher total comorbidity score (3.5 vs. 2.9, p < .001) compared to
patients who had no depressive symptoms. There were also higher proportions of patients
with depressive symptoms who were minorities (48% vs. 31%, p < .001), NYHA Class III
or IV (75% vs. 43%, p < .001) and had a history of myocardial infarction 64% vs. 53%, p = .
007) or COPD (20% vs. 13%, p = .02). Fewer patients with depressive symptoms were
taking angiotensin receptor blockers (19% vs. 30%, p = .004), beta blockers (80% vs. 88%,
p = .009), or digoxin (36% vs. 26%, p = .01), and fewer had a history of coronary bypass
surgery (15% vs. 28%, p < .001) or implanted cardioverter defibrillators (32% vs. 42%, p = .
034) when compared to patients with no depressive symptoms.
The overall mean BSI score was 0.72 ± 0.73, and 56% (n = 309) of the sample had anxiety
levels above the mean level of anxiety in healthy adults. Approximately 10% of the patients
in our sample had BSI scores higher than the mean anxiety level of psychiatric patients.
Table 2 compares the characteristics between patients who were anxious and not anxious.
Patients with symptoms of anxiety were more likely to be younger (61 vs. 64, p = .003), had
a lower average BMI (30 vs. 31, p = .036), worse DASI scores (10 vs. 19, p = .001), and
higher total comorbidity score (3.3 vs. 2.9, p = .01) compared to patients who were not
anxious. Among patients who were anxious, there were higher proportions of women (38%
vs. 28%, p = .018), minorities (43% vs. 29%, p < .001), NYHA Class III or IV (64% vs.
41%, p < .001), less than a high school education (33% vs. 17%, p < .001), comorbidities of
stroke (24% vs. 15%, p = .006) or myocardial infarction (62% vs. 50%, p = .008),
antidepressant use (26% vs. 13%, p < .001), and digoxin use (33% vs. 25%, p = .049 ), when
compared with patients who were not anxious. There were fewer patients with anxiety
symptoms taking angiotensin converting enzyme inhibitors (64% vs. 73%, p = .027) or who
had implanted cardioverter defibrillators (7% vs. 13%, p = .021) when compared to patients
without anxiety.
Of the total sample, 229 patients (41%) had neither depressive nor anxiety symptoms
(symptom-free), 130 (23%) had anxiety symptoms alone, 18 (3%) had depressive symptoms
alone, and 179 (32%) had both depressive symptoms and anxiety symptoms. The
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characteristics of these groups are compared in Table 1. Patients who had depressive
symptoms, anxiety symptoms, or both, were younger and had a higher proportion with
NYHA functional class III/IV compared to patients who were symptom-free. Patients who
had both depressive and anxiety symptoms included a higher proportion of minorities, a
lower average body mass index, and worse DASI and comorbidity scores than the 3 other
groups.
Coexistence of anxiety and depressive symptoms
Anxiety and depressive symptoms frequently coexisted in this sample. Of the 309 patients
with anxiety, 179 (58%) had comorbid depressive symptoms, while 130 (42%) had no
depressive symptoms. Of the 197 patients with depressive symptoms, 179 (91%) had
anxiety symptoms. There were also strong correlations between the BSI and BDI-II (r = .68,
p < .001).
In Figure 1, we compare the proportion of patients with none to minimal, mild, moderate,
and severe depressive symptoms among three categories of anxiety symptoms: 1) below the
mean anxiety level of healthy adults, 2) in between the mean anxiety level of healthy adults
and the mean level of psychiatric outpatients, and 3) above the mean anxiety level of
psychiatric outpatients. There was a significant difference in the proportions of none, mild,
moderate, and severe depressive symptoms among the different anxiety level groups (p < .
001). Of those patients with no anxiety symptoms (BSI < 0.35), 92% had none to minimal
depressive symptoms. Among those with anxiety symptoms above the mean of healthy
adults but below the mean level of psychiatric patients (BSI >0.35 and <1.7), about half
(49%) had none to minimal depressive symptoms, 26% had mild depressive symptoms, and
25% had moderate-severe depressive symptoms. In contrast, among patients with anxiety
symptoms above the mean of psychiatric patients (BSI >1.7), the majority (70%) had
moderate to severe symptoms of depression, 22% had mild symptoms of depression, and
only 7% had none to minimal symptoms.
Regression Results
In the logistic regression model (Table 3), depressive symptoms were the strongest predictor
of anxiety symptoms, after controlling for age, gender, minority status, education level,
NYHA class, DASI scores, total comorbidity score, and antidepressant use. For every 1-
point increase on the BDI-II, there was a 25% increase in the risk of experiencing anxiety
symptoms. Age was the only other significant variable in the model, with younger age
predicting the presence of anxiety symptoms. The model as a whole explained 49% of the
variance in anxiety symptoms, with depressive symptoms by itself explaining 29% of
variance.
Discussion
In this study, we found that depressive and anxiety symptoms frequently co-exist in patients
with HF. The vast majority of patients with depressive symptoms experienced comorbid
anxiety symptoms, and more than half of patients with anxiety symptoms had comorbid
depressive symptoms. Importantly, we found that as the severity of anxiety symptoms
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increased, there was a corresponding increase in the severity of depressive symptoms—
suggesting a possible dose-response relationship between anxiety and depressive symptoms
in patients with HF.
Using the BDI-II, we found that the prevalence of depressive symptoms in this sample was
35%. This prevalence is consistent with findings from a meta-analysis in which researchers
reported that 33% of patients with HF have depressive symptoms as measured with
questionnaires.5 We also found that 56% of our sample had BSI-anxiety scores above the
mean of healthy adults, and 10% had scores higher than the average anxiety level of
psychiatric patients. To our knowledge, ours is the only research team to use the BSI to
measure anxiety in patients with HF, so it is not possible to compare the rates of anxiety we
observed with other samples.
One of the unique findings of our study was that we were able to characterize the
coexistence of depressive symptoms and anxiety symptoms. Although previous researchers
have reported strong correlations between anxiety levels and depressive symptom levels in
patients with HF, to our knowledge, only one small study has reported the extent of
comorbidity. In 2005, Haworth et al.22 enrolled 100 mostly male outpatients with chronic
systolic HF and determined the presence of generalized anxiety disorder (GAD) (11%) and
depressive disorder (29%) using a structured clinical diagnostic interview. Approximately
9% of the sample had co-existing depressive disorder and GAD. Although other researchers
have reported strong correlations between depressive symptoms and anxiety symptoms,23–25
and higher rates of mortality among patients who have both depressive symptoms and
anxiety symptoms,26 none of these researchers reported the percentage of patients who
experienced comorbid depression and anxiety versus those who experience depression or
anxiety alone.
Although ours is the first study to more fully characterize the coexistence of depressive
symptoms and anxiety symptoms in patients with HF, our results are consistent with
findings from non-HF populations. For example, in a study of 479 psychiatric outpatients
with major depressive disorder, Zimmerman et al. found that 57% of psychiatric outpatients
with depression had a current, co-existing anxiety disorder, and an additional 14% had
clinically significant anxiety symptoms that did not meet the diagnostic threshold for an
anxiety disorder.27
Researchers have proposed two potential reasons for the high rates of comorbidity of
depression and anxiety in the general population: symptom overlap and shared
psychopathology.28 Symptom overlap means that patients may be labeled with anxiety or
depression simply because they are experiencing several symptoms that fit into either
category. According to the DSM-IV-TR, major depressive disorder and generalized anxiety
disorder share 4 overlapping symptoms: difficulty sleeping, difficulty concentrating, fatigue,
and psychomotor agitation/restlessness.29 In a study of 1,218 primary care patients with
major depressive disorder, generalized anxiety disorder, or both, researchers found that
patients with comorbid depression and anxiety endorsed significantly more of the 4
“overlapping” symptoms than patients with depression alone.28
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Although researchers have found that symptoms of anxiety and depression overlap in
primary care patients, it is unlikely that symptom overlap by itself would explain the high
rates of coexisting anxiety and depressive symptoms found in our sample of HF patients. In
the instruments that we used to measure anxiety and depressive symptoms, only one
symptom—restlessness—was listed on both instruments. Researchers have proposed that
high rates of comorbid anxiety and depression may be due instead to a shared
psychopathology or underlying factors that predispose certain individuals to both depression
and anxiety.28 For example, in twin studies, researchers have found a strong genetic link
between anxiety and depression.3031 However, this possibility has not been explored in
patients with HF.
In our regression model, we found that only two predictors of anxiety status: depressive
symptoms and younger age. Surprisingly, in contrast to what other researchers have
reported, functional status (both NYHA class and DASI scores) and comorbidities did not
predict anxiety symptoms. In Haworth et al.’s study of male outpatients with HF, predictors
of generalized anxiety disorder were NYHA class, comorbidities, and a history of mental
illness, with the strongest predictor being a history of mental illness. Overall, their model
explained 29% of the variance and was 86% accurate in predicting classification of anxiety.
Our results may differ from those of Haworth et al. because of our sample included women
and patients with diastolic and systolic HF, and we used self-report instruments to measure
anxiety instead of diagnostic interviews. We also included a more evenly distributed array of
patients with NYHA Class I/II vs. III/IV Classes—54% of patients had NYHA Class III or
IV HF, compared to 27% of patients with NYHA Class III/IV HF in Haworth et al.’s study.
Our finding of the frequent coexistence of anxiety and depression in patients with HF
indicates a need for researchers to develop—and nurses and clinicians to utilize—
interventions that can simultaneously treat both depression and anxiety. In their study on the
comorbidity of depression and anxiety in psychiatric outpatients, Zimmerman et al. reported
that the majority of patients with comorbid depression and anxiety expressed a desire to
receive treatment for both conditions.27 Unfortunately, at this time, no research has been
conducted testing interventions for the simultaneous treatment of depression and anxiety in
patients with HF. However, a large body of evidence shows that cognitive behavior therapy,
a non-pharmacological intervention, is effective for treating both depression and anxiety in
the general population.32 Future investigators who test cognitive behavior therapy
interventions in patients with HF should measure the effects of the intervention not only on
depressive symptoms, but on symptoms of anxiety as well.
Our study was limited by its cross-sectional nature; as such we cannot make any inferences
about causality of depression or anxiety. Our results are also limited by the use of
instruments to measure self-reported anxiety and depressive symptoms rather than
diagnostic interviews for major depressive disorder or generalized anxiety disorder.
However, patients with HF frequently experience clinically significant depressive and
anxiety symptoms that may not meet the diagnostic threshold for depressive disorder or
generalized anxiety disorder, and we feel it is important to include a broad spectrum of
anxiety and depressive symptoms in HF research. Finally, as this was a secondary data
analysis, we did not have information on patients’ past psychiatric history, counseling
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sessions, or anti-anxiety medications. Future research on this topic should include
measurement of patient’s lifetime history of anxiety and depression episodes, as well as
information on past or current treatment with counseling or anti-anxiety medications.
Conclusions
Nearly one-third of outpatients with HF experienced coexisting symptoms of anxiety and
depression. Patients at highest risk for experiencing anxiety symptoms include those who are
younger and those who have depressive symptoms. It is important for nurses and other
healthcare providers to recognize that there is a dose-response relationship between
depressive symptoms and anxiety. If a patient has moderate to severe symptoms of
depression, there is a strong likelihood that he or she is also experiencing anxiety symptoms.
Future research is needed to identify interventions that are effective for treating both
depressive symptoms and anxiety symptoms in patients with HF.
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• Patients with heart failure have high rates of anxiety
• Depression is the strongest predictor of anxiety in HF
• Patients may need treatment for both depression and anxiety
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Relationship between the level of anxiety symptoms and the level of depressive symptoms
*Data presented by number (n)
†BSI = Brief Symptom Inventory anxiety subscale; BSI ≤ 0.35: anxiety symptoms lower than the mean of healthy adults, BSI
0.351–1.7: anxiety symptoms higher than the mean anxiety level of healthy adults but lower than the mean level of psychiatric
patients; BSI > 1.7: anxiety symptoms higher than the mean level of psychiatric patients
‡BDI = Beck Depression Inventory; BDI 0–13: none to minimal depressive symptoms; BDI 14–19: mild symptoms; BDI 20–
28: moderate symptoms: BDI 29–63: severe symptoms
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Table 2
Comparison of patients with and without anxiety symptoms*
Characteristic No anxiety (n =247) Anxiety (n = 309) p
Age, mean ± SD, yrs 63.6 ± 11.5 60.6 ± 12.5 .003
Female, % 28.3 37.9 .018
†Minority, % 29.1 43 .001
Live alone, % 28.0 24.3 .313
Married, % 57.5 61.2 .380
LVEF, mean ± SD, % 35.3 ± 14.6 37.7 ± 15.0 .076
Body mass index, mean ± SD 31.1 ± 7.7 29.8 ± 7.2 .036
NYHA functional class, %
  Class I 11.8 5.5 <.001
  Class II 47.2 30.1
  Class III 33.7 45.0
  Class IV 7.3 19.4
Duke Activity Status Index, mean ± SD 18.8 ± 14.3 9.6 ± 11.2 <.001
Education level, %
  Less than high school 17.0 32.9 <.001
  High school graduate 27.1 20.2
  Some college or higher 55.9 46.9
Heart failure etiology, %
  Ischemic 50.6 54.6 .253
  Idiopathic 19.9 14.6
  Other 29.5 30.8
Comorbidity, %
  History of MI 50.4 61.8 .008
  History of CABG 27.6 19.9 .033
  Atrial fibrillation 44.3 38.7 .187
  Biventricular pacemaker 31.8 29.2 .505
  ICD 12.9 7.0 .021
  History of stroke 15.0 24.4 .006
  Diabetes mellitus 42.9 39.0 .346
  COPD 14.2 16.0 .573
Total Comorbidity Score 2.92 ± 1.69 3.32 ± 1.93 .01
Medications, %
  ACE inhibitor 73.0 64.1 .027
  Beta-blocker 87.8 83.3 .136
  Diuretic 75.5 71.0 .237
  Digoxin 25.0 32.8 .049
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Characteristic No anxiety (n =247) Anxiety (n = 309) p
  ARB 19.4 25.4 .097
  Antidepressants 12.9 25.8 <.001
*
p values were calculated using independent t-tests for continuous variables and the chi-square test of association for categorical variables, bolded
values highlight the statistically significant differences;
†
Minorities were defined as non-Caucasians (almost all minorities were African American)
LVEF = Left ventricular ejection fraction, NYHA = New York Heart Association functional class, MI = myocardial infarction, CABG = coronary
artery bypass graft, ICD = implanted cardiac defibrillator, COPD = chronic obstructive pulmonary disease, ACE = angiotensin converting enzyme,
ARB = angiotensin receptor blocker
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